Guillain-Barre Syndrome (GBS)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Guillain-Barre Syndrome

MalaCards integrated aliases for Guillain-Barre Syndrome:

Name: Guillain-Barre Syndrome 12 52 25 58 36 54 42 43 15 17 71
Guillain-Barré Syndrome 74 52 25 53 3 32
Fisher Syndrome 25 53 36
Gbs 52 25 58
Acute Inflammatory Demyelinating Polyneuropathy 52 71
Acute Inflammatory Polyneuropathy 52 25
Acute Inflammatory Demyelinating Polyradiculoneuropathy 52
Acute Inflammatory Demyelinating Polyradiculopathy 12
Acute Autoimmune Peripheral Neuropathy 52
Landry-Guillain-Barre-Strohl Syndrome 52
Acute Immune-Mediated Polyneuropathy 52
Acute Postinfectious Polyneuropathy 12
Variant of Guillain-Barre Syndrome 58
Guillain-Barré-Strohl Syndrome 52
Landry-Guillain-Barre Syndrome 25
Guillain-Barre-Strohl Syndrome 58
Acute Inflammatory Neuropathy 52
Acute Infectious Polyneuritis 25
Acute Infective Polyneuritis 12
Post-Infectious Polyneuritis 12
Landry's Ascending Paralysis 52
Postinfectious Polyneuritis 12
Post-Infective Polyneuritis 52
Miller Fisher Syndrome 71
Infectious Neuronitis 12
Variant of Gbs 58


Orphanet epidemiological data:

guillain-barre syndrome
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe); Age of onset: All ages; Age of death: any age;
variant of guillain-barre syndrome
Inheritance: Multigenic/multifactorial,Not applicable; Age of onset: All ages; Age of death: any age;


Orphanet: 58  
Rare neurological diseases

External Ids:

Disease Ontology 12 DOID:12842
MeSH 43 D020275
NCIt 49 C116345
SNOMED-CT 67 40956001
ICD10 32 G61.0
MESH via Orphanet 44 D020275
ICD10 via Orphanet 33 G61.0
UMLS via Orphanet 72 C0018378
UMLS 71 C0018378 C0393799 C3542501

Summaries for Guillain-Barre Syndrome

Genetics Home Reference : 25 Guillain-Barré syndrome is an autoimmune disorder that affects the nerves. Autoimmune disorders occur when the immune system malfunctions and attacks the body's own tissues and organs. In Guillain-Barré syndrome, the immune response damages peripheral nerves, which are the nerves that connect the central nervous system (the brain and spinal cord) to the limbs and organs. Specifically, the immune response affects a particular part of peripheral nerves called axons, which are the extensions of nerve cells (neurons) that transmit nerve impulses. Guillain-Barré syndrome can affect the neurons that control muscle movement (motor neurons); the neurons that transmit sensory signals such as pain, temperature, and touch (sensory neurons); or both. As a result, affected individuals can experience muscle weakness or lose the ability to feel certain sensations. Muscle weakness or paralysis are the characteristic features of Guillain-Barré syndrome. The weakness often begins in the legs and spreads to the arms, torso, and face and is commonly accompanied by numbness, tingling, or pain. Additional signs and symptoms of the condition include difficulty swallowing and difficulty breathing. Occasionally, the nerves that control involuntary functions of the body such as blood pressure and heart rate are affected, which can lead to fluctuating blood pressure or an abnormal heartbeat (cardiac arrhythmia). There are several types of Guillain-Barré syndrome, classified by the part of the peripheral nerve involved in the condition. The most common type of Guillain-Barré syndrome is acute inflammatory demyelinating polyradiculoneuropathy (AIDP). In AIDP, the immune response damages myelin, which is the covering that protects axons and promotes the efficient transmission of nerve impulses. In two other types of Guillain-Barré syndrome, acute motor axonal neuropathy (AMAN) and acute motor-sensory axonal neuropathy (AMSAN), the axons themselves are damaged by the immune response. In AMAN, only the axons of motor neurons are damaged. In AMSAN, the axons of sensory neurons are also damaged. Because of sensory nerve damage, affected individuals can lose the ability to sense the position of their limbs and can have abnormal or absent reflexes (areflexia). Miller Fisher syndrome, another type of Guillain-Barré syndrome, involves cranial nerves, which extend from the brain to various areas of the head and neck. Miller Fisher syndrome is characterized by three features: weakness or paralysis of the muscles that move the eyes (ophthalmoplegia), problems with balance and coordination (ataxia), and areflexia. People with this condition can have other signs and symptoms common in Guillain-Barré syndrome, such as muscle weakness. Guillain-Barré syndrome occurs in people of all ages. The development of the condition usually follows a pattern. Prior to developing the condition, most people with Guillain-Barré syndrome have a bacterial or viral infection. The first phase of Guillain-Barré syndrome, during which signs and symptoms of the condition worsen, can last up to four weeks, although the peak of the illness is usually reached in one to two weeks. During the second phase, called the plateau, signs and symptoms of Guillain-Barré syndrome stabilize. This phase can last weeks or months. During the recovery phase, symptoms improve. However, some people with Guillain-Barré syndrome never fully recover and can still experience excessive tiredness (fatigue), muscle weakness, or muscle pain.

MalaCards based summary : Guillain-Barre Syndrome, also known as guillain-barré syndrome, is related to pharyngeal-cervical-brachial variant of guillain-barre syndrome and miller fisher syndrome, and has symptoms including seizures, tremor and back pain. An important gene associated with Guillain-Barre Syndrome is PMP22 (Peripheral Myelin Protein 22), and among its related pathways/superpathways are Allograft rejection and NF-kappaB Signaling. The drugs 4-Aminopyridine and Interferon beta-1a have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and spinal cord, and related phenotypes are Reduced mammosphere formation and homeostasis/metabolism

Disease Ontology : 12 An autoimmune disease of peripheral nervous system that causes body's immune system to attack part of the peripheral nervous system.

NIH Rare Diseases : 52 Guillain-Barre syndrome (GBS) is a rare syndrome in which the body's immune system attacks part of the peripheral nervous system . The peripheral nervous system carries signals from the brain to the muscles. Symptoms of GBS include muscle weakness, numbness, and tingling sensations, which can increase in intensity until the muscles cannot be used at all (paralysis ). The exact cause of Guillain-Barre syndrome is unknown. In most cases, GBS occurs a few days or weeks after symptoms of a viral infection. In rare cases, GBS may run in families. A diagnosis of GBS is suspected when a person has symptoms suggestive of the syndrome. A variety of tests, including a spinal tap , may be completed to confirm the diagnosis. Treatment options may include plasma exchange (plasmapheresis) and immunoglobulin therapy .

MedlinePlus : 42 Guillain-Barre syndrome is a rare disorder that causes your immune system to attack your peripheral nervous system (PNS). The PNS nerves connect your brain and spinal cord with the rest of your body. Damage to these nerves makes it hard for them to transmit signals. As a result, your muscles have trouble responding to your brain. No one knows what causes the syndrome. Sometimes it is triggered by an infection, surgery, or a vaccination. The first symptom is usually weakness or a tingling feeling in your legs. The feeling can spread to your upper body. In severe cases, you become almost paralyzed. This is life-threatening. You might need a respirator to breathe. Symptoms usually worsen over a period of weeks and then stabilize. Guillain-Barre can be hard to diagnose. Possible tests include nerve tests and a spinal tap. Most people recover. Recovery can take a few weeks to a few years. Treatment can help symptoms, and may include medicines or a procedure called plasma exchange. NIH: National Institute of Neurological Disorders and Stroke

CDC : 3 Guillain-Barré (Ghee-YAN Bah-RAY) syndrome (GBS) is a rare, autoimmune disorder in which a person's own immune system damages the nerves, causing muscle weakness and sometimes paralysis. GBS can cause symptoms that last for a few weeks to several years. Most people recover fully, but some have permanent nerve damage. Some people have died of GBS.

NINDS : 53 Guillain-Barré syndrome (GBS) is a rare neurological disorder in which the body's immune system attacks part of the peripheral nervous system. It is one of several disorders involving weakness due to peripheral nerve damage caused by the person's immune system. Initial symptoms include unexplained sensations such as tingling in the feet or hands, or pain, followed by weakness on both sides of the body. The weakness can increase in intensity over a period of hours to days to weeks until the muscles cannot be used at all and the person is almost totally paralyzed. If breathing muscles are affected, the person is often put on a ventilator. Most individuals, however, have good recovery from even the most severe cases of GBS, although some continue to have some degree of weakness. The exact cause of Guillain-Barré syndrome is unknown. It can occur a few days or weeks after the person has had symptoms of a respiratory or gastrointestinal viral infection. Occasionally, surgery will trigger the syndrome. In rare instances, vaccinations may increase the risk of GBS. Recently, some countries worldwide have reported an increased incidence of GBS following infection with the Zika virus. A nerve conduction velocity (NCV) test, which measures the nerve's ability to send a signal, can aid the diagnosis. The cerebrospinal fluid that bathes the spinal cord and brain contains more protein than usual in someone with GBS, so a physician may decide to perform a spinal tap to obtain a sample of fluid to analyze.

KEGG : 36 Fisher syndrome is a variant of the Guillain- Barre syndrome (GBS) and its classical clinical triad consists of ophthalmoplegia, ataxia, and areflexia. It is a relatively rare neurological disorder, accounting for approximately 5% of acute inflammatory polyneuropathies. This disease is an immune-mediated condition and specific anti-ganglioside antibodies, especially IgG anti-GQ1b antibodies, are found in over 80% of the patients. Campylobacter and Haemophilus influenzae have been reported as infectious agents prior to the onset of Fisher syndrome. It has been reported that the median period required for the disappearance of ataxia was about 1 month, without therapy.

Wikipedia : 74 Guillain-Barré syndrome (GBS) is a rapid-onset muscle weakness caused by the immune system damaging the... more...

Related Diseases for Guillain-Barre Syndrome

Diseases in the Guillain-Barre Syndrome family:

Guillain-Barre Syndrome, Familial

Diseases related to Guillain-Barre Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1102)
# Related Disease Score Top Affiliating Genes
1 pharyngeal-cervical-brachial variant of guillain-barre syndrome 35.0 HP ACP1
2 miller fisher syndrome 33.4 TNF PMP22 MAG CD40LG
3 chronic inflammatory demyelinating polyradiculoneuropathy 33.3 PMP22 MPZ MBP HLA-DRB1 ALB
4 foot drop 31.3 PMP22 MPZ
5 polyradiculopathy 31.3 TNFRSF1B TNF PMP22 CD40LG
6 hepatitis e 31.1 TNF CD40LG ALB
7 demyelinating polyneuropathy 31.1 PMP22 MAG HP ALB
8 visceral leishmaniasis 30.9 TNF HLA-DRB1 ALB
9 myasthenia gravis 30.9 TNF MBP HLA-DQB1 CD40LG
10 allergic encephalomyelitis 30.9 MOG MBP
11 purpura 30.9 TNF CD79A CD40LG
12 membranous nephropathy 30.8 TNF CD79A ALB
13 quadriplegia 30.8 MOG MBP CCR6
14 leishmaniasis 30.7 TNF HLA-DRB1 HLA-DQB1 ALB
15 glomerular disease 30.7 CD79A ALB
16 neurilemmoma 30.7 PMP22 MPZ MBP
17 pustulosis of palm and sole 30.7 TNFRSF1B TNF CCR6
18 filariasis 30.7 TNFRSF1B TNF ALB
19 bacteriuria 30.6 CD79A CD40LG ALB
21 brachial plexus neuropathy 30.6 PMP22 MPZ CD40LG
22 scarlet fever 30.6 TNF CD40LG ALB
23 pulmonary tuberculosis 30.6 TNF HP HLA-DRB1 HLA-DQB1 ALB
24 acute retrobulbar neuritis 30.6 MBP CD40LG
25 endocarditis 30.5 TNFRSF1B TNF ALB
26 hantavirus hemorrhagic fever with renal syndrome 30.5 TNF CD40LG ALB
27 vasculitis 30.5 TNFRSF1B TNF CD79A CD40LG
28 neurosarcoidosis 30.5 TNFRSF1B TNF MOG
29 anuria 30.5 HP CD40LG ALB
30 peripheral nervous system disease 30.5 TNFRSF1B TNF PMP22 MPZ MOG MBP
31 polyneuropathy 30.5 TNF PMP22 MPZ MBP MAG CD40LG
32 microscopic polyangiitis 30.5 TNF HLA-DRB1
33 parotitis 30.5 CD79A CD40LG ALB
34 lupus erythematosus 30.5 TNFRSF1B TNF HLA-DRB1 HLA-DQB1 CD40LG
35 echinococcosis 30.5 TNF HLA-DRB1 CD40LG
36 vogt-koyanagi-harada disease 30.5 HLA-DRB1 HLA-DQB1 FAS
37 lyme disease 30.5 TNF HLA-DRB1 HLA-DQB1 CD40LG
38 alcoholic hepatitis 30.4 TNFRSF1B TNF ALB
39 pericarditis 30.4 TNF CD40LG ALB
40 spondylitis 30.4 TNFRSF1B TNF CCR6
41 churg-strauss syndrome 30.4 TNF HLA-DRB1 CD40LG
42 nervous system disease 30.4 TNF MOG CCR6 ALB
43 lipoid nephrosis 30.4 CD79A CD40LG ALB
44 henoch-schoenlein purpura 30.4 CD79A CD40LG ALB
45 respiratory failure 30.4 TNF HCRT CD40LG CCR6 ALB
46 reactive arthritis 30.4 TNF HP HLA-DRB1 CCR6
47 splenic abscess 30.3 CD40LG ALB
48 chickenpox 30.3 TNFRSF1B TNF CD40LG CCR6 ALB
49 graft-versus-host disease 30.3 TNF HLA-DRB1 HLA-DQB1 FAS
50 viral hepatitis 30.3 TNF HLA-DRB1 FAS CD40LG ALB

Graphical network of the top 20 diseases related to Guillain-Barre Syndrome:

Diseases related to Guillain-Barre Syndrome

Symptoms & Phenotypes for Guillain-Barre Syndrome

UMLS symptoms related to Guillain-Barre Syndrome:

seizures, tremor, back pain, ophthalmoplegia, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness, cerebellar ataxia, neuralgia

GenomeRNAi Phenotypes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 ALB CCR6 CD79A FAS MAG MOG

MGI Mouse Phenotypes related to Guillain-Barre Syndrome:

# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.19 ACP1 ALB CCR6 CD40LG CD79A DAAM2
2 cellular MP:0005384 10.18 ACP1 ALB CD40LG CD79A FAS HLA-DQB1
3 cardiovascular system MP:0005385 10.14 ACP1 ALB CCR6 CD40LG DAAM2 FAS
4 hematopoietic system MP:0005397 10.1 CCR6 CD40LG CD79A FAS HLA-DQB1 HP
5 immune system MP:0005387 10 ACP1 ALB CCR6 CD40LG CD79A FAS
6 muscle MP:0005369 9.65 ACP1 ALB DAAM2 FAS HCRT HLA-DQB1
7 nervous system MP:0003631 9.47 CCR6 CD40LG CD79A FAS HCRT HLA-DQB1

Drugs & Therapeutics for Guillain-Barre Syndrome

Drugs for Guillain-Barre Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
4-Aminopyridine Approved Phase 2 504-24-5 1727
Interferon beta-1a Approved, Investigational Phase 2 145258-61-3 6438354
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
4 Complement System Proteins Phase 2
5 Immunoglobulins Phase 2
6 Antibodies Phase 2
7 Immunoglobulins, Intravenous Phase 2
8 Immunologic Factors Phase 2
9 Rho(D) Immune Globulin Phase 2
10 gamma-Globulins Phase 2
11 Pharmaceutical Solutions Phase 2
12 Potassium Channel Blockers Phase 2
13 Anti-Infective Agents Phase 2
14 Interferon-beta Phase 2
15 interferons Phase 2
16 Antiviral Agents Phase 2
17 Adjuvants, Immunologic Phase 2
18 Hormones Phase 2
19 Antineoplastic Agents, Hormonal Phase 2
20 glucocorticoids Phase 2
21 Hormone Antagonists Phase 2
22 Anti-Inflammatory Agents Phase 2
Sodium citrate Approved, Investigational 68-04-2
Thiamine Approved, Investigational, Nutraceutical, Vet_approved 59-43-8, 70-16-6 1130
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
26 Calcium, Dietary
27 Vitamins
28 Vitamin B Complex
29 Thiamin
30 Citrate
31 Hemostatics
32 Autoantibodies
33 Immunoglobulin G
34 Vaccines
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show top 50) (show all 65)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety Study of GB-0998 for Guillain-Barré Syndrome Completed NCT02342184 Phase 3 GB-0998
2 Phase III Clinical Trial of NPB-01 in Patients With Guillain-Barré Syndrome Completed NCT02221271 Phase 3 NPB-01
3 Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study Unknown status NCT02029378 Phase 2 Eculizumab
4 Efficacy and Safety of Preventive Mechanical Ventilation in Adults With Guillain Barré Syndrome Completed NCT00167622 Phase 2
5 Small Volume Plasma Exchange (SVPE) for Guillain-Barré Syndrome Patients in Bangladesh: A Safety and Feasibility Study Completed NCT02780570 Phase 2
6 Assessment of Chronic GBS Improvement With Use of 4-AP Completed NCT00056810 Phase 2 4-aminopyridine (4-AP)
8 A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of AVONEX When Used in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Completed NCT00099489 Phase 2 Interferon Beta-1a
9 Effect of IVIg on Pregnancy Rate of Patient With Recurrent Implantation Failure With Immunological Causes Completed NCT03174964 Phase 2 IVIg
10 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
11 Early Onset Immunotherapy by Intravenous Immunoglobulin in Well-characterized Onconeural-antibody-positive Paraneoplastic Neurological Syndromes Completed NCT02343211 Phase 2 Immunoglobulin
12 A Randomized Double Blind Placebo Controlled Trial to Assess the Safety and Efficacy of Intravenous Immunoglobulin (IVIG) in Children With Japanese Encephalitis in Nepal Completed NCT01856205 Phase 2 Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]
13 A Phase 1b Study to Evaluate the Safety, Tolerability and Drug-Drug Interactions of ANX005 and Intravenous Immunoglobulin (IVIg) in Subjects With Guillain Barré Syndrome Recruiting NCT04035135 Phase 1, Phase 2 ANX005;Intravenous immunoglobulin
14 An Open-label, Single Arm, Multi-centre, Phase II Study Investigating Safety, Tolerability, Efficacy, Pharmacodynamics and Pharmacokinetics of Imlifidase in Patients With Guillain-Barré Syndrome, in Comparison With Matched Control Patients Recruiting NCT03943589 Phase 2 Imlifidase
15 Phase I, Placebo-Controlled, Double-Blind Study To Evaluate The Safety, Tolerability, AND Immunogenicity Of GLS-5700, Administered ID Followed By Electroporation In Dengue Virus-Seropositive Adults Completed NCT02887482 Phase 1
16 Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults Completed NCT02809443 Phase 1
17 Phase I Trial To Evaluate The Safety Of CK0801 In Treatment-Resistant Guillain-Barré Syndrome (GBS) Not yet recruiting NCT03773328 Phase 1
18 Perception and Multisensory Integration in Neurological Patients Using fMRI Unknown status NCT01469858
19 sCD163 as a Potential Biomarker in Guillain- Barré Syndrome Unknown status NCT02582853
20 The Changes of Cytokines in Guillain Barré Syndrome: the Correlation With Clinical Manifestations and Skin Innervation Unknown status NCT00173199
21 Change of Nerve Conduction Properties in IVIg Dependent Neuropathies Unknown status NCT01655394
22 Detection of Peripheral Blood Biomarkers in Intermediate Phase Spinal Cord Injury: Correlation With Neurological and Functional Outcomes, and Comparison to Other Central and Peripheral Neurological Conditions. Unknown status NCT01516385
23 The Safety of GSK Biological's H1N1 Pandemic Vaccine in Manitoba, Canada Unknown status NCT01421251
24 Improving Influenza Vaccination Rates in Nurses Through Electronic Text Message Reminders : a Randomised Controlled Trial Unknown status NCT02589574
25 Effects of Robotic-assisted Gait Training In Non-Ambulatory Patients After Guillain-Barré Syndrome : A Randomized Controlled Trial Completed NCT02883270
26 Prospective Study on Swallowing/Breathing Interactions in Severe Guillain Barre Syndrome. Completed NCT01024088
27 Risk of Guillain-Barré Syndrome Following Meningococcal Conjugate (MCV4) Vaccination Completed NCT00575653
28 Comparison of Intravenous Immunoglobulin and Plasma Exchange in Treatment of Mechanically Ventilated Children With Guillain Barre Syndrome. A Randomized Study. Completed NCT01306578 IVIG
29 A Feasibility Study for Daily Use of a Brain Computer Interface for Communication in an ICU Completed NCT01005524
30 Regional Citrate Anticoagulation in Plasma Exchange Treatment Completed NCT01370200
31 The Effectiveness and Safety of Human Lumbar Puncture Assist Device (LPat) Completed NCT03710278
32 Cervarix Long-term Safety Surveillance Using the PGRx Information System (PGRx Study) Completed NCT01498627
33 A Phase IV Study to Assess the Safety of Menveo Vaccine Being Used by HMO Subjects Aged 11-21 Years of Age Completed NCT01452464
34 Phase 4 Study of Post-License Safety Evaluation of Influenza Split Vaccine Completed NCT02136017
35 A Post-marketing Study to Monitor the Safety of Beijing Tiantan Biological's Influenza Virus Vaccine Administered in Chinese Subjects Aged 60 Years or Older Completed NCT01906593
36 Active Surveillance of Adverse Events Following Immunization Among Healthcare Workers Immunized With the Influenza Vaccine Completed NCT01318876
37 Short and Long-Term Electronic Surveillance of a Large Number of Healthcare Workers Following Administration of an Adjuvanted Ph1n1 Vaccine Completed NCT01289418
38 A Post-marketing Safety Study of SIBP's Inactivated, Split-virion Influenza Vaccine Administered in Chinese Subjects Aged 3 Years and Older Completed NCT02133456
39 Recovery of Visual Acuity in Vestibular Deficits Completed NCT00411216
40 Evaluating the B1 Status in Eating Disorder Female Adolescent Patients Completed NCT02164487
41 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Completed NCT03206541
42 Randomized Evaluation of Live Attenuated vs.Trivalent Inactivated Influenza Vaccines in Schools (RELATIVES)Pilot Study Completed NCT01995851
43 Pilot Project on Clinical Tolerance to a Live Attenuated Vaccine Against Influenza (Flumist®) in the Context of Influenza Vaccination in a Population Allergic to Eggs. Completed NCT02142491
44 International GBS Outcome Study (IGOS): A Prospective INC Study on Clinical and Biological Predictors of Disease Course and Outcome in Guillain-Barré Syndrome (GBS). Recruiting NCT01582763
45 A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement Recruiting NCT03801135 Fibrinogen concentrate
46 New Biomarkers in Acute and Chronic Inflammatory Demyelinating Polyradiculoneuropathies Recruiting NCT04249752
47 Early Prediction of Respiratory and Autonomic Complications of GBS Using Neuromuscular Ultrasound Recruiting NCT04166357
48 Determining the Association Between Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity Recruiting NCT03941184
49 Neuro-COVID-19: Neurological Complications of COVID-19 Recruiting NCT04418609
50 Neurologic Manifestations of COVID 19 in Children Recruiting NCT04379089

Search NIH Clinical Center for Guillain-Barre Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Immunoglobulins, Intravenous

Cochrane evidence based reviews: guillain-barre syndrome

Genetic Tests for Guillain-Barre Syndrome

Anatomical Context for Guillain-Barre Syndrome

MalaCards organs/tissues related to Guillain-Barre Syndrome:

Brain, Testes, Spinal Cord, T Cells, Heart, Eye, Lung

Publications for Guillain-Barre Syndrome

Articles related to Guillain-Barre Syndrome:

(show top 50) (show all 8643)
# Title Authors PMID Year
Neurological complications associated with emerging viruses in Brazil. 61 42
31975402 2020
Pharmacological treatment other than corticosteroids, intravenous immunoglobulin and plasma exchange for Guillain-Barré syndrome. 42 61
31981368 2020
IL-8 as a potential biomarker in Guillain-Barre Syndrome. 61 42
32096474 2019
Treatment-related Fluctuations in Guillain Barre Syndrome and the Conundrum of Additional Cycles of Plasmapheresis. 61 52
29184340 2017
Hypocretin/orexin and narcolepsy: new basic and clinical insights. 54 61
19555382 2010
[Evaluation of myelin basic protein levels with receiver operating characteristic curves for diagnosis of multiple sclerosis]. 54 61
19246291 2009
Guillain-Barré syndrome. 61 54
16271648 2005
T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. 61 54
16170091 2005
Hypocretins (orexins): clinical impact of the discovery of a neurotransmitter. 61 54
15979356 2005
Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome. 61 54
14653854 2004
Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. 61 54
12676332 2003
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10. 54 61
11912115 2002
CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. 54 61
11756606 2001
Investigation of serum response to PMP22, connexin 32 and P(0) in inflammatory neuropathies. 61 54
11438177 2001
Anti-alpha B-crystallin immunoreactivity in inflammatory nervous system diseases. 54 61
11200685 2000
Anti-PMP22 antibodies in patients with inflammatory neuropathy. 61 54
10713353 2000
[Antiganglioside antibodies in the pathogenesis of autoimmune neuropathies]. 61 54
10377820 1999
T helper type 2 like cytokine responses to peptides from P0 and P2 myelin proteins during the recovery phase of Guillain-Barré syndrome. 61 54
9455979 1997
Soluble complement receptor type 1 in serum and cerebrospinal fluid of patients with Guillain-Barré syndrome and multiple sclerosis. 61 54
8707926 1996
[Anti-glycoconjugate antibodies and dysglobulinemic or dysimmune peripheral neuropathies]. 61 54
8881439 1996
Anti-alpha- and beta-tubulin IgM antibodies in dysimmune neuropathies. 61 54
8583236 1995
Serum factor in Miller-Fisher variant of Guillain-Barré syndrome and neurotransmitter release. 61 54
7905957 1994
Antibody responses to P0 and P2 myelin proteins in Guillain-Barré syndrome and chronic idiopathic demyelinating polyradiculoneuropathy. 61 54
7689591 1993
T cell responses to myelin proteins in Guillain-Barré syndrome. 54 61
1279128 1992
In vitro demyelination by serum antibody from patients with Guillain-Barré syndrome requires terminal complement complexes. 54 61
1718212 1991
Cerebrospinal fluid and serum antiphospholipid antibodies in multiple sclerosis, Guillain-Barré syndrome and systemic lupus erythematosus. 54 61
2094193 1990
Antibodies to gangliosides and myelin proteins in Guillain-Barré syndrome. 61 54
2194427 1990
Zika virus promotes CCN1 expression via the CaMKIIα-CREB pathway in astrocytes. 61
31957543 2020
A review on Zika virus outbreak, epidemiology, transmission and infection dynamics. 61
32158705 2020
Guillain-Barré syndrome: The first documented COVID-19-triggered autoimmune neurologic disease: More to come with myositis in the offing. 61
32518172 2020
Guillain-Barré syndrome related to SARS-CoV-2 infection. 61
32461235 2020
Hypoalbuminemia in Guillain-Barré syndrome. 61
32362470 2020
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report. 61
32499912 2020
The neurology of COVID-19 revisited: A proposal from the Environmental Neurology Specialty Group of the World Federation of Neurology to implement international neurological registries. 61
32464367 2020
Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis. 61
32393650 2020
Hepatitis E: an expanding epidemic with a range of complications. 61
32251845 2020
Is COVID-19-related Guillain-Barré syndrome different? 61
32445789 2020
COVID-19: A Global Threat to the Nervous System. 61
32506549 2020
Guillain-Barré syndrome related to COVID-19 infection. 61
32350026 2020
Neurological Manifestations of COVID-19: A systematic review and current update. 61
32412088 2020
Facial diplegia, a possible atypical variant of Guillain-Barré Syndrome as a rare neurological complication of SARS-CoV-2. 61
32410788 2020
Post SARS-CoV-2 Guillain-Barré syndrome. 61
32422529 2020
Are Repeated Cycles of Intravenous Immunoglobulin Justified in Patients With Poorly Responsive Guillain-Barré Syndrome? 61
32549948 2020
Guillain-Barré syndrome as a complication of SARS-CoV-2 infection. 61
32360440 2020
Is a second course of intravenous immunoglobulin treatment in Guillain-Barré syndrome justifiable? 61
32362471 2020
Guillain-Barré syndrome and chronic inflammatory demyelinating polyradiculoneuropathy after alemtuzumab therapy in kidney transplant recipients. 61
32299841 2020
A Unique Case of a Pediatric Patient With Blastic Plasmacytoid Dendritic Cell Neoplasm, Guillain Barre Syndrome, and Hemophagocytic Lymphohistiocytosis. 61
30933025 2020
Posterior reversible encephalopathy and Guillain-Barré syndrome: which came first, the chicken or the egg? A review of literature. 61
32506357 2020
A horse and a zebra: an atypical clinical picture including Guillain-Barré syndrome, recurrent fever and mesenteric lymphadenopathy caused by two concomitant infections. 61
32128685 2020
Pearls & Oy-sters: Guillain-Barré syndrome: An unusual presentation of acute intermittent porphyria. 61
32561680 2020

Variations for Guillain-Barre Syndrome

Expression for Guillain-Barre Syndrome

Search GEO for disease gene expression data for Guillain-Barre Syndrome.

Pathways for Guillain-Barre Syndrome

Pathways related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
Show member pathways
10 10.34 MBP MAG

GO Terms for Guillain-Barre Syndrome

Cellular components related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of membrane GO:0016021 10.22 TNFRSF1B TNF PMP22 MPZ MOG MAG
2 plasma membrane GO:0005886 10.18 TNFRSF1B TNF PMP22 MPZ MOG MBP
3 cell surface GO:0009986 9.8 TNF MBP HLA-DRB1 FAS CD40LG CCR6
4 external side of plasma membrane GO:0009897 9.7 TNF MOG HLA-DRB1 FAS CD79A CD40LG
5 membrane raft GO:0045121 9.65 TNFRSF1B TNF MAG FAS CD79A
6 myelin sheath GO:0043209 9.26 PMP2 MPZ MBP MAG
7 compact myelin GO:0043218 8.8 PMP22 MBP MAG

Biological processes related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.78 PMP22 MPZ MBP HCRT
2 myelination GO:0042552 9.58 PMP22 MPZ MBP
3 positive regulation of chemokine (C-X-C motif) ligand 2 production GO:2000343 9.46 TNF MBP
4 necroptotic signaling pathway GO:0097527 9.43 TNF FAS
5 extrinsic apoptotic signaling pathway GO:0097191 9.43 TNFRSF1B TNF FAS
6 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.37 HLA-DRB1 HLA-DQB1
7 regulation of immunoglobulin secretion GO:0051023 9.32 TNF CD40LG
8 tumor necrosis factor-mediated signaling pathway GO:0033209 9.26 TNFRSF1B TNF FAS CD40LG
9 immune response GO:0006955 9.23 TNFRSF1B TNF MBP HLA-DRB1 HLA-DQB1 FAS
10 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.16 HLA-DRB1 HLA-DQB1

Molecular functions related to Guillain-Barre Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 8.96 HLA-DRB1 HLA-DQB1
2 tumor necrosis factor-activated receptor activity GO:0005031 8.62 TNFRSF1B FAS

Sources for Guillain-Barre Syndrome

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....